Timing is always the trick, and it is incredibly hard to pick the top or the bottom. The price you paid "5-6 months ago" will look like "bad" timing now, but in the medium term it could end up looking extremely "good" - if IMU closes one or more commercial deals and ends up multiples of the current SP. So it also depends on how you view risk, and how long you are prepared to hold on to a stock if you believe the fundamentals are good.
In my own case, I learned a lot from LYC. I thought the fundamentals were excellent so I bought in during the long period when LYC was a renowned "dog" stock - having been smashed down and down repeatedly while they ironed out problems with their rare earth refinery plant. Unfortunately the upturn took longer than I expected and LYC dropped another 60% in the year I held it, before they turned the corner.
I did hold on, and I also averaged down. However, by the time the SP started to rise again I was so spooked by the whole experience that I sold as soon as I could show a modest profit (around 15% from memory). Had I held just a little longer, of course, I would have made many times that - because the fundamentals were indeed always excellent. I just should have trusted my own assessment.
Of course no-one can guarantee that IMU will succeed in the same way - it remains a speculative stock. My own view is that the chances of success, and the likely scale of that success, are far higher than the current SP would seem to indicate - but that's only my view and you need to make your own assessment.
The personal lesson I learned from LYC was to research, research and then do some more research, and to take comments on HC with a large grain of salt. That includes both Negative and Positive comments, unless they cite good evidence or give credible analysis. I certainly enjoy the positive "up ramper" comments far more than the negative "down ramper" comments - but I try not to let either of them influence my own decisions, which I try to keep focussed on the facts, as best as I can understand them.
Which reminds me - your Brother in law. I'm sorry to hear of your loss. The further we go through life the more likely it becomes that we will know someone who has lost a fight with cancer. Every story is different - the common thread is grief and loss.
However, unless your brother in law had gastric cancer and was living overseas in one of the 22 locations for the Her-vaxx Phase 1b and 2 trial (all locations were in SE Asia, India or Eastern Europe) - then he was almost certainly not "actually trying a product from IMU."
2.5 years ago long predates the PD1-vaxx trial, which only started on 17 Dec 2020, and the Check-vacc trial of course is in breast cancer and only started late last year.
The only other possibility would have been the earlier phase of the B-vaxx trial, if he happened to be living in Ohio USA. B-vaxx was part of the portfolio of B-cell drugs licensed to Imugene when the did the deal with Prof Kaumaya in June 2018.
A final sad thought - the last of the 22 sites for the original Her-vaxx Ph 2 trial was: "ARENSIA Exploratory Medicine LLC Kapitanivka, Ukraine." There is a small village/town of Kapitanivka but I believe the trial site is actually on the Western edge of Kyiv. Who would have thought, 3 years ago, that one of Imugene's clinical trial sites would end up in a war zone? We have no way of knowing if any of the remaining patients are based there (unlikely - there are 22 trial sites - but it is possible). However were can be sure that there will be plenty of people in Ukraine suffering cancer, and other illnesses, and now trying to live through a war as well. A real battle added to their personal inner battle. And not just Ukraine. Add all the other war zones in the world - Ethiopia; Yemen; Sudan....
It makes me reflect on my own good fortune to live in a relatively safe and prosperous nation, and what I can do to help others who are lfar ess fortunate.
Dave
IMU Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
(20min delay)